Legend Biotech(US:LEGN) Zhi Tong Cai Jing·2025-09-08 02:14Core Viewpoint - Legend Biotech (LEGN.US) is considering a secondary listing outside the United States due to strong investor interest in the pharmaceutical sector [1] Group 1: Listing Considerations - Potential locations for the secondary listing include Hong Kong, Singapore, and London, with Hong Kong being particularly noted for potentially enhancing the company's valuation [1] - The company is still in the consideration phase and may ultimately decide against pursuing a secondary listing [1] Group 2: Company Background - Legend Biotech was founded in 2014 and went public on NASDAQ in 2020 [1] - The company specializes in CAR-T cell immunotherapy for cancer treatment, with its flagship product, ciltacabtagene autoleucel, having received FDA approval in the United States [1]